Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
| ▸ | CKS1B | P61024 | 2/20 | 0.49 |
| ▸ | SKP1 | P63208 | 2/20 | 0.49 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.43 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30089468 | 0.86 | MAP4K4 (0.48) | MAP4K4CKS1BSKP1SKP2PRMT5 | |
| SCHEMBL23612106 | 0.86 | MAP4K4 (0.48) | MAP4K4CKS1BSKP1SKP2PRMT5 | |
| SCHEMBL16249699 | 0.81 | PTPN11 (0.52) | MAP4K4CKS1BSKP1SKP2NAMPT | |
| SCHEMBL28935546 | 0.81 | JAK3 (0.47) | MAP4K4ALDH1A1JAK3 | |
| SCHEMBL18163277 | 0.80 | MAP4K4 (0.54) | MAP4K4CKS1BSKP1SKP2PRMT5 | |
| SCHEMBL22576378 | 0.79 | CKS1B (0.53) | MAP4K4CKS1BSKP1SKP2DDB1 | |
| SCHEMBL30501971 | 0.79 | CKS1B (0.53) | MAP4K4CKS1BSKP1SKP2DDB1 | |
| SCHEMBL4055019 | 0.79 | PDE10A (0.64) | MAP4K4CKS1BSKP1SKP2PDE10A | |
| SCHEMBL23625711 | 0.78 | MAP4K4 (0.61) | MAP4K4CKS1BSKP1SKP2PRMT5 | |
| SCHEMBL29727809 | 0.78 | MAP4K4 (0.61) | MAP4K4CKS1BSKP1SKP2PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101556-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2024-03-28 | — | — | US | disclosed |
| CN-117561253-A | Compounds and compositions for treating disorders related to STING activity | 艾福姆德尤股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-4274659-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-4245758-A2 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR | Xynomic Pharmaceuticals, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| US-11753409-B2 | Crystalline salts of a B-RAF kinase inhibitor | XYNOMIC PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753409-B2 | Crystalline salts of a B-RAF kinase inhibitor | XYNOMIC PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| EP-3700530-B1 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR | XYNOMIC PHARMACEUTICALS INC (US) | 2023-04-19 | — | — | EP | disclosed |
| US-20230115274-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-13 | — | — | US | disclosed |
| EP-4085061-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| CN-115279770-A | Compounds and compositions for treating diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2022-11-01 | — | — | CN | disclosed |
| WO-2022150543-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022150543-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| US-20220204506-A1 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-06-30 | — | — | US | disclosed |
| US-11306086-B2 | Crystalline salts of a B-RAF kinase inhibitor | XYNOMIC PHARMACEUTICALS, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| WO-2021138419-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC, (US) | 2021-07-08 | — | — | WO | disclosed |
| WO-2021138419-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC, (US) | 2021-07-08 | — | — | WO | disclosed |
| US-20200283433-A1 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR | XYNOMIC PHARMACEUTICALS, INC. | 2020-09-10 | — | — | US | disclosed |
| US-20200283433-A1 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR | XYNOMIC PHARMACEUTICALS, INC. | 2020-09-10 | — | — | US | disclosed |
| US-8889684-B2 | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-8889684-B2 | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283433-A1 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR | BRAF, RAF1, ARAF | MAP4K4 26/4885CKS1B 168/4885SKP1 51/4885 |
| US-20220204506-A1 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR | BRAF, RAF1, ARAF | MAP4K4 26/4885CKS1B 168/4885SKP1 51/4885 |
| US-20230115274-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | MAP4K4 1819/4885CKS1B 1742/4885SKP1 4060/4885 |
| US-20240101556-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | MAP4K4 2055/4885CKS1B 1766/4885SKP1 3942/4885 |
| US-11306086-B2 | Crystalline salts of a B-RAF kinase inhibitor | BRAF, RAF1, ARAF | MAP4K4 26/4885CKS1B 168/4885SKP1 51/4885 |
| US-11753409-B2 | Crystalline salts of a B-RAF kinase inhibitor | BRAF, RAF1, ARAF | MAP4K4 26/4885CKS1B 168/4885SKP1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.